Moderna to cut 10% of workforce, CEO tells staff, as part of $1.5B savings...
Moderna is laying off 10% of its global staff as part of a broad cost-cutting program across the business. CEO Stéphane Bancel relayed the news to employees on Thursday morning in a message reviewed by...
View ArticleRadella hopes muscle-sparing obesity approach will make it stand out
Radella Pharmaceuticals is bucking the trend. Where most obesity startups are focused on developing incretins or amylins — the two main classes that have been shown to work convincingly in the disease...
View ArticleAlnylam sharply raises sales projections for Amvuttra group on heels of new...
A recent label expansion is sending sales of Alnylam’s Amvuttra through the roof. The drug pulled in $492.0 million in revenue in the second quarter, up 114% from the $230.1 million it reported in the ...
View ArticleWuXi AppTec targets $981M raise; Stockpiling leads to Leqembi sales jump
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. WuXi AppTec is looking to raise 7.7 billion Hong Kong dollars ($981...
View ArticleTrump administration to launch a unified health records system
President Donald Trump announced plans on Wednesday to build a healthcare records system that would make it a lot easier for patients to share their data with doctors, targeting one of ...
View ArticleIgnoring China's biotech industry is no longer an option. It's a recipe for...
Big Pharma has a habit of clustering around drug targets. So it was business as usual when GSK stepped in Monday morning to pick up an early-stage PDE3/4 inhibitor on the heels of Merck’s ...
View ArticleEndpoints livestream: Is China’s biotech boom unstoppable?
Earlier this month, we hosted a Post-Hoc Live with venture capital investor Zach Weinberg, who argued for a protectionist approach to China’s biotech boom to safeguard the US ecosystem of drug...
View ArticleImmuneOnco, Instil Bio’s PD-L1xVEGF posts encouraging mid-stage data
ImmuneOnco's PD-L1xVEGF bispecific antibody has promising data from an early cut of a Phase 2 study in certain lung cancer patients, the Shanghai-based biotech’s US partner Instil Bio said Thursday. ...
View ArticlePrime Medicine is selling $125M in stock; Nuvectis stops work on ovarian...
Plus, news about Neurocrine Biosciences: Prime Medicine’s $125M offering: The biotech is selling 38 million shares at $3.30 apiece. Earlier this month, Prime announced the departure of Chief ...
View ArticleBristol Myers raises revenue guidance for the year, prepares for major...
Bristol Myers Squibb is upping its revenue guidance for 2025 by $700 million. The pharma company said Thursday that it now expects to bring in between $46.5 billion and $47.5 billion ...
View ArticleAbbVie again hikes guidance as it eyes neuro, obesity and PD-1xVEGF deals
AbbVie beat revenue estimates across nearly its entire portfolio in the second quarter, save for aesthetics and Humira. The company said Thursday that it had revenue of $15.4 billion in the ...
View ArticleSword moves beyond digital physical therapy
Sword Health started in virtual musculoskeletal care. That initial focus put it on our radar as a rival to newly public Hinge Health — and potentially, one of the next digital ...
View ArticleTrump demands pharma CEOs implement 'most favored nation' pricing within 60 days
President Donald Trump stepped up his campaign to get large drugmakers to lower their prices, posting letters to more than a dozen major pharma companies demanding that they bring their US prices in...
View ArticleFDA chief wants more harmony between CBER and CDER
FDA Commissioner Marty Makary told biotech and pharma CEOs that he wants to better align the agency's drug and biologics centers, just as one official was — at least temporarily — tapped to lead both....
View ArticleHRSA unveils pilot program for 340B rebate model
The Health Resources and Services Administration announced on Thursday that it’s rolling out a pilot program to test a rebate model for certain 340B drug discounts. The announcement comes as a ...
View ArticleMerck will shed 6,000 jobs as it eyes $3B in cost cuts
Merck will cut about 6,000 positions, or roughly 8% of its workforce, as part of the $3 billion cost-cutting program that it disclosed during second-quarter earnings this week, a spokesperson confirmed...
View Article4DMT’s eye gene therapy cuts need for injections that treat diabetic macular...
4D Molecular Therapeutics' gene therapy version of Regeneron's Eylea reduced the number of injections that patients with diabetic macular edema need over a year. However, it's unclear if and when the...
View ArticleFDA approves Lenz's eye drop for presbyopia, a tricky market for other...
Lenz Therapeutics, a small San Diego biotech, will launch its presbyopia eye drop in the US next quarter after getting a thumbs-up from the FDA on Thursday. Lenz will market the aceclidine-based
View ArticleBayer says pharma sales exceed expectations, bumps full-year guidance
Bayer has raised its full-year guidance because of a steadily improving pharma business, in an early glimpse of its second-quarter performance before its earnings event next week. The German...
View ArticleNovo Nordisk's shakeup goes beyond a new CEO; Former FDAer snags regulatory...
→ Novo Nordisk didn’t make the splashy hire with its new CEO, and like other recent large pharma transitions — think AbbVie and Bristol Myers Squibb — the Danish giant chose to promote from within....
View Article